Trump expands Section 232 campaign

Tariffs are back, but in a narrower and more durable form. Instead of swinging at nearly everything, the Trump administration is now using Section 232 — the national-security trade law — to go industry by industry. The big move came on April 2, when Trump imposed new tariffs on patented pharmaceuticals and rewired existing Section 232 duties on steel, aluminum, and copper. Basically, this is the administration turning a broad trade fight into a series of targeted sector cases. (federalregister.gov) U.S. national security. That sounds like a military tool, but the law is broad enough to cover supply chains, industrial capacity, and economic resilience. Trump used it in his first term for steel and aluminum. In this term, the list has spread to autos, copper, critical minerals, semiconductors, timber and lumber, trucks and buses, and now pharmaceuticals. (cov.com)hat proclamation says imports of patented drugs, active pharmaceutical ingredients, and key starting materials threaten national security, and it imposes new tariffs. Second, he signed a separate proclamation tightening and restructuring the metals regime for steel, aluminum, and copper. (federalregister.gov) ### Why are dr(cov.com)cturing for branded medicines and critical ingredients. The White House framed that as both a health-security and supply-chain problem. The proclamation draws a sharp line between patented branded products and generics — generics are not being tariffed “at this time,” which tells you the goal is not a blanket tax on every pill coming into the country. (whitehouse.gov)cated. The tariff applies to patented pharmaceuticals and related ingredients, not to all medicines, and it starts after a delay — 120 days for certain large companies and 180 days for smaller ones. There are also carveouts and reduced-rate pathways, so the effective burden will vary a lot by product and company structure. (whitehouse.gov)nt tariff theory, it can build separate legal records for specific industries and then act under Section 232. Trade lawyers tracking the policy now describe a widening campaign across multiple sectors, not a one-off drug measure. That makes the policy more fragmented, but also potentially stickier. (cov.com) ### What a(whitehouse.gov)he delay before the tariffs bite gives companies time to adjust, which is probably one reason markets did not treat the announcement like an immediate earnings disaster. But the catch is that supply chains for branded drugs are slow to move, heavily regulated, and expensive to duplicate. (cnbc.com) ### And what about prices? That is the part nobody(cov.com)reimbursement systems all complicate the pass-through. But the pressure has to land somewhere — margins, launch timing, insurer negotiations, or patient costs. Even when the direct hit is softened, the broader signal is clear: global pharma pricing strategy now has a U.S. trade-policy variable in it. (advisory.com) ### Bottom line? Trump is not just reviving old tariffs. He is rebuilding trade policy around Section 232, one sector at a tim(cnbc.com) (cov.com)